Table 8. In vitro cytotoxicity of the selected iridium(iii) porphyrin complexes against a panel of human cancer cell lines ^{a b c} .

	IC50 (μM) b					IC50 (μM)		PI c	Uptake d	Log P e
	HeLa	HepG2	MCF-7	HCT116	HCC827	NCI-H460 (dark)	NCI-H460 (light)
1d′	0.37 ± 0.10	1.60 ± 0.21	0.71 ± 0.04	0.42 ± 0.06	0.55 ± 0.11	0.46 ± 0.10	0.04 ± 0.003	11.5	235.9 ± 9.81	2.67
2a	0.17 ± 0.1	2.1 ± 0.3	0.65 ± 0.2	0.14 ± 0.04	2.29 ± 0.50	1.22 ± 0.03	0.11 ± 0.08	11.1	147.6 ± 6.4	3.03
2c	0.03 ± 0.01	0.93 ± 0.1	0.16 ± 0.1	0.14 ± 0.1	1.1 ± 0.3	0.15 ± 0.05	0.009 ± 0.004	16.7	309.7 ± 46.7	2.96
2e	0.10 ± 0.1	2.4 ± 0.2	0.73 ± 0.5	0.11 ± 0.03.	0.69 ± 0.01.	0.16 ± 0.04	0.006 ± 0.002	26.7	158.7 ± 29.5	3.23
2f	0.10 ± 0.1	0.94 ± 0.1	0.26 ± 0.1	0.4 ± 0.2	1.23 ± 0.10	0.31 ± 0.04	0.03 ± 0.002	10.3	131.3 ± 10.2	2.76
3	7.9 ± 0.5	>100	>100	23 ± 3.3	50 ± 3.6	2.9 ± 0.02	0.12 ± 0.02	24.2	116.2 ± 20.6	3.11
4	0.10 ± 0.01	1.32 ± 0.10	0.12 ± 0.02	0.25 ± 0.08	1.27 ± 0.32	0.11 ± 0.005	0.005 ± 0.001	23.1	305.1 ± 57.2	2.83
[IrIII(oep)Cl(CO)]	>50	>50	>50	>50	>50	>50	19.70 ± 1.0	>2.5	34.1 ± 2.8	2.38
Cisplatin	3.80 ± 0.51	6.18 ± 0.82	13.20 ± 1.03	6.94 ± 0.54	9.61 ± 0.81	3.96 ± 0.48	4.61 ± 0.31	0.86	—	—

^aHeLa, cervical epithelial carcinoma; HepG2, hepatocellular carcinoma; MCF-7, breast carcinoma; HCT-116, colorectal carcinoma; HCC827, non-small cell lung carcinoma; NCI-H460, non-small cell lung carcinoma.

^bIC₅₀ values were examined by MTT assay after incubation of drugs for 72 h.

^cPI = IC₅₀(dark)/IC₅₀(light).

^dCellular uptake was determined by the iridium content (μg) in the cellular proteins (g) after treatment of the NCI-H460 cells with each complex (1 μM) for 2 h.

^eLipophilicity was determined by measuring the ratio of the amount of iridium (μg) in each complex partitioned in n-octanol and saline solution (0.9%, w/v).